GOSSAMER BIO, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GOSSAMER BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $292.00K, a 21.51% decline year-over-year.
- GOSSAMER BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $469.00K, a 66.90% increase year-over-year.
- GOSSAMER BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-03-31 was $372.00K, a 6.90% increase year-over-year.
- GOSSAMER BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $281.00K, a 264.94% increase year-over-year.
- GOSSAMER BIO, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $840.00K, a 33.55% increase from fiscal 2024.
- GOSSAMER BIO, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $629.00K, a 41.67% increase from fiscal 2023.
- GOSSAMER BIO, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $444.00K, a 63.43% decline from fiscal 2022.
- GOSSAMER BIO, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $1.21M, a 7.68% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-03-31 | $292.00K 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $840.00K 10-K · filed 2026-03-17 | |
| 2025-09-30 | $469.00K 10-Q · filed 2025-11-05 | |
| 2025-03-31 | $372.00K 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $629.00K 10-K · filed 2026-03-17 | |
| 2024-09-30 | $281.00K 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $348.00K 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $444.00K 10-K · filed 2026-03-17 | |
| 2023-09-30 | $77.00K 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $367.00K 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $1.21M 10-K · filed 2025-03-13 | |
| 2022-09-30 | $620.00K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $595.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $1.31M 10-K · filed 2024-03-05 | |
| 2021-09-30 | $556.00K 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $759.00K 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $1.30M 10-K · filed 2023-03-17 | |
| 2020-09-30 | $744.00K 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $556.00K 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |